Impacting Human Health: Moderna’s 2021 ESG Report

Jun 24, 2022 9:00 AM ET

In its 2021 ESG Report, Moderna outlines its corporate responsibility strategy and defines five guiding focus areas for ongoing and future efforts:

The report also includes updates to the progress Moderna has made to date:

25% of total doses of its COVID-19 vaccine in 2021 were delivered to low- and middle-income countries.
40% of Moderna’s U.S. workforce identifies as racially or ethnically diverse, up from 35% in 2020.
Moderna announced its Global Public Health Strategy to:
- Advance vaccines targeting 15 pathogens identified as the biggest public health risks into clinical studies by 2025
- Launch mRNA Access
- Expand its COVID-19 patent pledge
- Establish an mRNA Manufacturing Facility in Kenya, Africa
Moderna formed a new collaboration with the Institute for Life Changing Medicines to develop a new mRNA therapeutic (mRNA-3351) for Crigler-Najjar type 1 (CN-1), an ultra-rare disease. The goal of this partnership is to make an mRNA therapy for the treatment of CN-1 available at no cost to patients and their families.
Moderna affirmed its commitment to sustainability by pledging to achieve net-zero carbon emissions in by 2030. With its engineering and manufacturing teams, Moderna is designing the company roadmap to embed sustainability by design in its current facilities and future manufacturing sites.

Media Contact:
Katherine O’Malley
Executive Director, Communications